Repositioning of Old Drugs for Novel Cancer Therapies: Continuous Therapeutic Perfusion of Aspirin and Oseltamivir Phosphate with Gemcitabine Treatment Disables Tumor Progression, Chemoresistance, and Metastases
Open Access
Abstract
Metastatic pancreatic cancer has an invariably fatal outcome, with an estimated median progression-free survival of approximately six months employing our best combination chemotherapeutic regimens. Once drug resistance develops, manifested by increased primary tumor size and new and growing metastases, patients often die rapidly from their disease. Emerging evidence indicates that chemotherapy may contribute to the development of drug resistance through the upregulation of epithelial–mesenchymal transition (EMT) pathways and subsequent cancer stem cell (CSC) enrichment. Neuraminidase-1 (Neu-1) regulates the activation of several receptor tyrosine kinases implicated in EMT induction, angiogenesis, and cellular proliferation. Here, continuous therapeutic targeting of Neu-1 using parenteral perfusion of oseltamivir phosphate (OP) and aspirin (ASA) with gemcitabine (GEM) treatment significantly disrupts tumor progression, critical compensatory signaling mechanisms, EMT program, CSC, and metastases in a preclinical mouse model of human pancreatic cancer. ASA- and OP-treated xenotumors significantly inhibited the metastatic potential when transferred into animals.Keywords
Funding Information
- Natural Sciences and Engineering Research Council of Canada (388697)
- NSERC Alliance (388697)
- the Josefowitz Family (388697)
- ENCYT Technologies Inc. (388697)
This publication has 72 references indexed in Scilit:
- Safety, Tolerability, and Pharmacokinetics of Intravenous Oseltamivir: Single- and Multiple-Dose Phase I Studies with Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2012
- RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasisNature, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Distant metastasis occurs late during the genetic evolution of pancreatic cancerNature, 2010
- The patterns and dynamics of genomic instability in metastatic pancreatic cancerNature, 2010
- Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancerProceedings of the National Academy of Sciences, 2010
- Pancreatic cancer: molecular pathogenesis and new therapeutic targetsNature Reviews Gastroenterology & Hepatology, 2009
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem CellsCell, 2008
- Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cellsProceedings of the National Academy of Sciences, 2006
- Complex networks orchestrate epithelial–mesenchymal transitionsNature Reviews Molecular Cell Biology, 2006